

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : VBI-2902,Aluminum Phosphate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VBI-2902 is a monovalent Covid-19-specific vaccine expressing the SARS-CoV-2 spike protein. The adaptive Phase 1/2 clinical study will evaluate the safety, tolerability, and immunogenicity of VBI-2902, adjuvanted with aluminum phosphate.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
March 09, 2021
Lead Product(s) : VBI-2902,Aluminum Phosphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
